{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06024239",
            "orgStudyIdInfo": {
                "id": "M23-893"
            },
            "organization": {
                "fullName": "AbbVie",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)",
            "officialTitle": "A Multiple Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Subjects, Subjects With Generalized Anxiety Disorder (GAD) and Subjects With Bipolar Disorder",
            "therapeuticArea": [
                "Mental Health",
                "Other"
            ],
            "study": "a-study-to-evaluate-the-pharmacokinetics-safety-and-tolerability-of-abbv-in-healthy-adult-participants-participants-with-generalized-anxiety-disorder-gad-and-participants-with-bipolar-disorder-bpd"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-19",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-19",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-30",
            "studyFirstSubmitQcDate": "2023-08-30",
            "studyFirstPostDateStruct": {
                "date": "2023-09-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AbbVie",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD)."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers",
                "Generalized Anxiety Disorder (GAD)",
                "Bipolar Disorder (BPD)"
            ],
            "keywords": [
                "ABBV-932",
                "Generalized Anxiety Disorder (GAD)",
                "Bipolar Disorder (BPD)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 96,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A, ABBV-932",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ABBV-932 once daily (QD) for 14 days.",
                    "interventionNames": [
                        "Drug: ABBV-932"
                    ]
                },
                {
                    "label": "Part A, Placebo for ABBV-932",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive placebo for ABBV-932 QD for 14 days.",
                    "interventionNames": [
                        "Drug: Placebo for ABBV-932"
                    ]
                },
                {
                    "label": "Part B, ABBV-932",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ABBV-932 QD for 28 days.",
                    "interventionNames": [
                        "Drug: ABBV-932"
                    ]
                },
                {
                    "label": "Part B, Placebo for ABBV-932",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive placebo for ABBV-932 QD for 28 days.",
                    "interventionNames": [
                        "Drug: Placebo for ABBV-932"
                    ]
                },
                {
                    "label": "Part C, ABBV-932",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ABBV-932 QD for 28 days.",
                    "interventionNames": [
                        "Drug: ABBV-932"
                    ]
                },
                {
                    "label": "Part C, Placebo for ABBV-932",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive placebo for ABBV-932 QD for 28 days.",
                    "interventionNames": [
                        "Drug: Placebo for ABBV-932"
                    ]
                },
                {
                    "label": "Part D, ABBV-932",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ABBV-932 QD for 42 days.",
                    "interventionNames": [
                        "Drug: ABBV-932"
                    ]
                },
                {
                    "label": "Part D, Placebo for ABBV-932",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive placebo for ABBV-932 QD for 42 days.",
                    "interventionNames": [
                        "Drug: Placebo for ABBV-932"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ABBV-932",
                    "description": "Capsule; oral",
                    "armGroupLabels": [
                        "Part A, ABBV-932",
                        "Part B, ABBV-932",
                        "Part C, ABBV-932",
                        "Part D, ABBV-932"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo for ABBV-932",
                    "description": "Capsule; oral",
                    "armGroupLabels": [
                        "Part A, Placebo for ABBV-932",
                        "Part B, Placebo for ABBV-932",
                        "Part C, Placebo for ABBV-932",
                        "Part D, Placebo for ABBV-932"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Observed Plasma Concentration (Cmax)",
                    "description": "Cmax will be assessed.",
                    "timeFrame": "Up to Day 28"
                },
                {
                    "measure": "Time to Cmax (Tmax)",
                    "description": "Tmax will be assessed.",
                    "timeFrame": "Up to Day 28"
                },
                {
                    "measure": "Plasma Concentrations at Pre-dose or at the End of a Dosing Interval (Ctrough)",
                    "description": "Ctrough will be assessed.",
                    "timeFrame": "Up to Day 28"
                },
                {
                    "measure": "Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau)",
                    "description": "AUCtau will be assessed.",
                    "timeFrame": "Up to Day 28"
                },
                {
                    "measure": "Number of Participants with Adverse Events (AEs)",
                    "description": "An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.",
                    "timeFrame": "Baseline to Day 129"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* For healthy volunteer cohort:\n\n  -- Body mass index (BMI) is \\>= 18.0 to \\<= 32.0 kg/m2 after rounding to the tenths decimal.\n* For participants with generalized anxiety disorder (GAD) or bipolar disorder (BPD)\n\n  * Participants with GAD or BPD (as confirmed by MINI) meet participant psychiatric history criteria described in the protocol.\n\nExclusion Criteria:\n\n- History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ABBVIE CALL CENTER",
                    "role": "CONTACT",
                    "phone": "844-663-3742",
                    "email": "abbvieclinicaltrials@abbvie.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "ABBVIE INC.",
                    "affiliation": "AbbVie",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Collaborative Neuroscience Research CNS /ID# 260270",
                    "status": "RECRUITING",
                    "city": "Los Alamitos",
                    "state": "California",
                    "zip": "90720",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.80307,
                        "lon": -118.07256
                    }
                },
                {
                    "facility": "Acpru /Id# 255945",
                    "status": "RECRUITING",
                    "city": "Grayslake",
                    "state": "Illinois",
                    "zip": "60030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.34447,
                        "lon": -88.04175
                    }
                },
                {
                    "facility": "Hassman Research Institute Marlton Site /ID# 260271",
                    "status": "RECRUITING",
                    "city": "Marlton",
                    "state": "New Jersey",
                    "zip": "08053",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.89122,
                        "lon": -74.92183
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Related Info",
                    "url": "https://www.abbvieclinicaltrials.com/study/?id=M23-893"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001008",
                    "term": "Anxiety Disorders"
                },
                {
                    "id": "D000001714",
                    "term": "Bipolar Disorder"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000068105",
                    "term": "Bipolar and Related Disorders"
                },
                {
                    "id": "D000019964",
                    "term": "Mood Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4324",
                    "name": "Anxiety Disorders",
                    "asFound": "Anxiety Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4996",
                    "name": "Bipolar Disorder",
                    "asFound": "Bipolar Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M226",
                    "name": "Bipolar and Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21835",
                    "name": "Mood Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}